TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Regulations for the Cosmetic Products Industry

Regulations for the Cosmetic Products Industry

 Regulation (EC) No. 1223/2009 is the primary legislation governing the cosmetics products industry in Europe. First published in the Official Journal of the European Union, Volume 52, on the 22 December 2009, it has been applied in full since 11 July 2013. The purpose of this cosmetics Regulation is to safeguard public health, with due regard to animal welfare, and to harmonise the rules in the European Economic Area (EEA) in order to achieve a single market for cosmetic products.

A ‘cosmetic product’ is any substance or mixture intended to be placed in contact with the external parts of the human body or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours.

Only cosmetic products for which a legal or natural person is designated within the Community as ‘Responsible Person’ (RP), shall be placed on the market as per Article 4 of Regulation (EC) No. 1223/2009. The RP may be the manufacturer, importer or person to whose order a cosmetic product is manufactured. The RP can be an individual or a legally registered company, must be based within the EEA and is responsible for the safety of the product which includes ensuring the product has undergone a safety assessment. The address of the RP should appear on the cosmetic labelling and would normally be the manufacturer or, where the manufacturer is based outside the EEA, the importer. The manufacturer may designate, by written mandate, a person established within the Community as the responsible person who shall accept the responsibility in writing.

The RP must review all the requirements outlined in Regulation No. 1223/2009 against their procedures and amend them accordingly. Before placing a cosmetic product on the market in the EEA, the RP must ensure that the cosmetic product is safe for use and meets the requirements of Regulation (EC) No. 1223/2009. The name and address of the RP must be on the label of the cosmetic product and in the Product Information File (PIF). A cosmetic product does not require approval or a licence before being placed on the market, and the PIF must be available at the address on the label.

For each cosmetic product placed on the market, the responsible person must ensure compliance with the following as set out in Regulation (EC) No. 1223/2009:

  • Adherence to the RP requirements as stipulated in per Article 4.
  • Notification to CPNP (Cosmetic Product Notification Portal) as per Article 13.
  • Include a Cosmetic Product Safety Report (CPSR) ensuring that the cosmetic product has undergone a safety assessment and a cosmetic product safety report is available.
  • Provision of the Product Information File (PIF) as per Article 11. This file must be available by the RP at the address displayed on the label of the cosmetic product.
  • Labelling as per Article 19.
  • Adherence to Claims as per Regulation (EU) 655/2013.

A distributor is a natural or legal person in the supply chain, other than the manufacturer or the importer, who makes a cosmetic product available on the Community market.

The obligations of the distributors as per Regulation (EC) No. 1223/2009 are as follows:

  • Ensure labelling requirements as per Article 19.
  • Confirm traceability within the supply chain.
  • Ensure the date of minimum durability specified, where applicable under Article 19(1), has not passed.
  • Take corrective action on non-compliant products and prevent non-conforming product entering the market.
  • Confirm storage or transport conditions do not jeopardise its compliance with the requirements set out in this Regulation.
  • Co-operate with the Competent Authorities as required.

The national competent authorities conduct regular inspections of manufacturers of cosmetic products to ensure compliance with GMP. Article 8 of Regulation (EC) No. 1223/2009 requires the manufacture of cosmetic products to comply with GMP standards as per ISO 27716.2007.

If you would like further information or wish to discuss how PharmaLex can support you with  cosmetic product’s regulation or compliance, please connect with us on +353 1 846 4742 or email us at contactirl@pharmalex.com.

References:

  1. http://www.erpacosmetics.com/what-is-a-responsible-person/
  2. https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf

 

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
6h

At PharmaLex, one of our core values is expanding our global community. In March, we welcomed Japan, East Asia, and Southeast Asia into our global pharmaceutical #productdevelopment as a result of a merger agreement with Ascent Development Services.
https://lnkd.in/eGFf_AKv

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for